{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:15:31Z","timestamp":1793834131806,"version":"4.6.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40265-022-01748-6","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T06:02:40Z","timestamp":1659938560000},"page":"1221-1228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Tapinarof Cream 1%: First Approval"],"prefix":"10.1007","volume":"82","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"1748_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113176","author":"N Fern\u00e1ndez-Gallego","year":"2021","unstructured":"Fern\u00e1ndez-Gallego N, S\u00e1nchez-Madrid F, Cibrian D. Role of AHR ligands in skin homeostasis and cutaneous inflammation. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10113176.","journal-title":"Cells"},{"key":"1748_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215424","author":"M Furue","year":"2019","unstructured":"Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20215424.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1748_CR3","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","volume":"84","author":"R Bissonnette","year":"2021","unstructured":"Bissonnette R, Stein Gold L, Rubenstein DS, et al. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021;84(4):1059\u201367.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1748_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40257-021-00649-w","volume":"23","author":"AM L\u00e9","year":"2022","unstructured":"L\u00e9 AM, Torres T. New topical therapies for psoriasis. Am J Clin Dermatol. 2022;23(1):13\u201324.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1748_CR5","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","volume":"137","author":"SH Smith","year":"2017","unstructured":"Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Investig Dermatol. 2017;137(10):2110\u20139.","journal-title":"J Investig Dermatol"},{"key":"1748_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01722-2","author":"E Freitas","year":"2022","unstructured":"Freitas E, Gooderham M, Torres T. New topical therapies in development for atopic dermatitis. Drugs. 2022. https:\/\/doi.org\/10.1007\/s40265-022-01722-2.","journal-title":"Drugs"},{"key":"1748_CR7","unstructured":"Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information; 2022. https:\/\/www.vtama.com\/docs\/DMVT_VTAMA_PI.pdf. Accessed 4 Jul 2022."},{"key":"1748_CR8","unstructured":"Dermavant Sciences. FDA approves Dermavant\u2019s VTAMA\u00ae (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults: first topical novel chemical entity launched for psoriasis in the U.S. in 25\u00a0years [media release]. 24 May 2022. https:\/\/www.dermavant.com\/."},{"key":"1748_CR9","unstructured":"Dermavant Sciences. Dermavant clinical trials; 2022. https:\/\/www.dermavant.com\/clinical-trials\/. Accessed 8 Jun 2022."},{"key":"1748_CR10","unstructured":"National Products Administration (NMPA). Psoriasis drug benvitimod cream approved for marketing; 2019. https:\/\/www.nmpa.gov.cn\/. Accessed 29 May 2022."},{"issue":"3","key":"1748_CR11","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/j.jaad.2021.04.103","volume":"85","author":"L Stein Gold","year":"2021","unstructured":"Stein Gold L, Rubenstein DS, Peist K, et al. Tapinarof cream 1% once daily and benvitimod 1% twice daily are 2 distinct topical medications. J Am Acad Dermatol. 2021;85(3):e201\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"1748_CR12","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1097\/CM9.0000000000001221","volume":"133","author":"L Cai","year":"2020","unstructured":"Cai L, Chen GH, Lu QJ, et al. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J (Engl). 2020;133(24):2905\u20139.","journal-title":"Chin Med J (Engl)"},{"key":"1748_CR13","unstructured":"Dermavant Sciences. Dermavant enters into exclusive license agreement with JT for development and commercialization of tapinarof in Japan [media release]. 15 Jan 2020. http:\/\/www.dermavant.com."},{"key":"1748_CR14","unstructured":"Torii Pharmaceutical Co. Torii signs exclusive license agreement with JT for development and commercialization of tapinarof in Japan [media release]. 19 Feb 2020. https:\/\/www.torii.co.jp\/en\/release\/2020\/20200115_E.pdf."},{"key":"1748_CR15","unstructured":"Dermavant Sciences. Dermavant Sciences announces closing of transaction with GSK for purchase of rights to tapinarof [media release]. 21 Aug 2018. http:\/\/www.dermavant.com."},{"key":"1748_CR16","unstructured":"GlaxoSmithKline. Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof [media release]. 12 Jul 2018. http:\/\/www.gsk.com."},{"key":"1748_CR17","unstructured":"Stiefel. Stiefel, a GSK company, enters into an agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis [media release]. 30 May 2012. http:\/\/www.stiefel.com."},{"key":"1748_CR18","unstructured":"Welichem Biotech Inc. Welichem and Stiefel, a GSK company, complete the acquisition by Stiefel of the novel anti-inflammatory agent, WBI-1001 [media release]. 31 Jul 2012. http:\/\/www.welichem.com."},{"issue":"1","key":"1748_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40257-021-00641-4","volume":"23","author":"JE Jett","year":"2022","unstructured":"Jett JE, McLaughlin M, Lee MS, et al. Tapinarof cream 1% for extensive plaque psoriasis: a maximal use trial on safety, tolerability, and pharmacokinetics. Am J Clin Dermatol. 2022;23(1):83\u201391.","journal-title":"Am J Clin Dermatol"},{"issue":"24","key":"1748_CR20","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","volume":"385","author":"MG Lebwohl","year":"2021","unstructured":"Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219\u201329.","journal-title":"N Engl J Med"},{"key":"1748_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.1171","author":"B Strober","year":"2022","unstructured":"Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.1171.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1748_CR22","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jaad.2018.10.037","volume":"80","author":"K Robbins","year":"2019","unstructured":"Robbins K, Bissonnette R, Maeda-Chubachi T, et al. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol. 2019;80(3):714\u201321.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1748_CR23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaad.2020.04.181","volume":"84","author":"L Stein Gold","year":"2021","unstructured":"Stein Gold L, Bhatia N, Tallman AM, et al. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: secondary efficacy and patient-reported outcomes. J Am Acad Dermatol. 2021;84(3):624\u201331.","journal-title":"J Am Acad Dermatol"},{"key":"1748_CR24","doi-asserted-by":"publisher","unstructured":"Lebwohl M, Del Rosso J, Hong CH, et al. Tapinarof cream for the treatment of plaque psoriasis: efficacy and safety by baseline disease characteristics and skin type in a phase 2b randomized study [poster]. SKIN. 2020;4(5):s30. https:\/\/doi.org\/10.25251\/skin.4.supp.30.","DOI":"10.25251\/skin.4.supp.30"},{"key":"1748_CR25","doi-asserted-by":"publisher","unstructured":"Bissonnette R, Stein Gold L, Kircik L, et al. Efficacy of tapinarof cream by body region in subjects with plaque psoriasis in a phase 2b randomized controlled study [poster]. SKIN. 2020;4(5):s47. https:\/\/doi.org\/10.25251\/skin.4.supp.69.","DOI":"10.25251\/skin.4.supp.69"},{"issue":"1","key":"1748_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaad.2018.06.047","volume":"80","author":"J Peppers","year":"2019","unstructured":"Peppers J, Paller AS, Maeda-Chubachi T, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019;80(1):89-98.e3.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1748_CR27","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jaad.2020.05.135","volume":"84","author":"AS Paller","year":"2021","unstructured":"Paller AS, Stein Gold L, Soung J, et al. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. J Am Acad Dermatol. 2021;84(3):632\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1748_CR28","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1016\/j.jaad.2021.03.006","volume":"85","author":"R Bissonnette","year":"2021","unstructured":"Bissonnette R, Gold LS, Rubenstein DS, et al. Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapy. J Am Acad Dermatol. 2021;85(1):e39\u201340.","journal-title":"J Am Acad Dermatol"},{"key":"1748_CR29","unstructured":"Eichenfield LF, Silverberg JI, Bissonnette R, et al. Tapinarof cream 1% once daily for the treatment of moderate-to-severe atopic dermatitis in children and adults: the pivotal phase III ADORING clinical program [abstract 575 + poster]. Br J Dermatol. 2022;186(4):E136-E."}],"updated-by":[{"DOI":"10.1007\/s40265-022-01768-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000}},{"DOI":"10.1007\/s40265-022-01771-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01748-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01748-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01748-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T09:27:03Z","timestamp":1662370023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01748-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1748"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01748-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"8 August 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-022-01771-7","URL":"https:\/\/doi.org\/10.1007\/s40265-022-01771-7","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-022-01768-2","URL":"https:\/\/doi.org\/10.1007\/s40265-022-01768-2","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}